StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Axsome Therapeutics's price to sales ratio was 10.1× on Nov 11, 2026, against 13.6× a year earlier. Over the last 4 years it ranged from 9.7× to 62.2×, with a median of 14.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202610.1×−6.3
2025Dec 31, 202516.4×+4.3
2024Dec 31, 202412.1×−4.7
2023Dec 29, 202316.9×–

More Axsome Therapeutics figures

See a number that looks wrong?